ArticleRespiratory medicine case reports2025
Endobronchial mucormycosis successfully treated with pharmacologic therapy: A rare case report.
Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 36-year-old female patient who did not have a previous history of any disease visited our institution because of shortness of breath. The patient was first diagnosed with diabetes upon admission. Chest computed tomography (CT) scan showed a lesion that completely obstructed the left main bronchus and pneumonia. Due to hypoxia, the patient was placed on mechanical ventilation and admitted to the intensive care unit. Bronchoscopy was performed, and results revealed complete atelectasis with a soft tissue mass at the left main bronchus. Bronchoscopic biopsy confirmed that the patient's condition was endobronchial mucormycosis. Treatment with liposomal amphotericin B was started. After 1 week, atelectasis improved based on the chest radiography result. The patient was successfully extubated. However, 4 weeks after treatment, bronchoscopy still showed complete atelectasis with purulent secretion and a soft tissue mass. After 6 weeks, liposomal amphotericin B was switched to isavuconazole, with a duration of 2 months. After completing the treatment, bronchoscopy showed no endobronchial lesion. Herein, we present a rare case of rapidly progressing endobronchial mucormycosis in a young patient who did not have a previous history of any disease and who was successfully managed with pharmacological therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.